LexaGene Targets Multi-Billion Dollar Industries with LX6 Pathogen Detection Instrument
In our latest exclusive interview, Alexander Smith travels to Boston, Massachusetts to visit our client LexaGene (LXG: TSXV) at its newly leased 17,500-square-foot facility. LexaGene’s President and CEO, Dr. Jack Regan, shows us how the LX6 prototype functions by taking us through its typical pathogen detection process.
LexaGene’s patented microfluidic system was invented by company founder and CEO, Dr. Jack Regan. Dr. Regan was a lead scientist in developing a predecessor instrument designed for bio-warfare surveillance that was adopted by the Department of Homeland Security for the BioWatch Program.
To learn how LexaGene’s technology works by utilizing single-use disposable cartridges to concentrate and purify genetic material, click here.
If you’re not already a member of our newsletter and you invest in TSX Venture stocks, what are you waiting for? Subscribe today. Only our best content will land in your inbox.